Meeting News CoverageMeeting Highlights

Dutasteride may increase adherence to active surveillance in early stage prostate cancer

ASCO 2011 Genitourinary Cancers Symposium

ORLANDO — Dutasteride increased adherence to active surveillance by nearly 40% in a cohort of men with early stage prostate cancer, according to findings presented in advance of the of the 2011 Genitourinary Cancers Symposium.

Neil Fleshner, MD, MPH, head of Urology at the University Health Network in Toronto, Canada, presented data on behalf of the Reduction with Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) study.

“We used this phase 3 multicenter study to see if we could employ a commonly used drug to improve the compliance with active surveillance for men who elect this as their strategy to manage early stage prostate cancer,” Fleshner said. He noted that most of the men in this particular population were not likely to die from their disease.

“Many men who choose active surveillance have anxiety about disease progression,” he said. “We wanted to see if this drug could improve that.”

There were 302 eligible men aged 48 to 82 involved in the trial. Repeat 12-core biopsies were performed at 1.5 years and 3 years if there was no cause and at other times if biopsy was warranted or desired. “Some men simply no longer want to observe their cancer,” Fleshner said.

The primary endpoint was time to progression. Pathological progression was defined as a Gleason score greater than 6, at least 4 cores positive, or greater than 50% of any core positive. Therapeutic progression was defined as radical prostatectomy, radiation therapy or hormonal ablation, according to study results.

“Dutasteride (Avodart, GlaxoSmithKline) reduced the time to prostate cancer progression by about 40%,” Fleshner said. He noted the relative risk reduction of 38.9% (95% CI, 12.4%–57.4%). “This 40% reduction significantly improves adherence to active surveillance.”

Fleshner said that 23% of men in the placebo group and 36% of men in the treatment group had no cancer detected in their final biopsy.

“There is no evidence of increased Gleason score progression in the dutasteride arm compared to placebo,” he added. “Drug-related adverse events were similar to those previously reported for dutasteride.”

For more information:

Twitter Follow HemOncToday.com on Twitter.

ASCO 2011 Genitourinary Cancers Symposium

ORLANDO — Dutasteride increased adherence to active surveillance by nearly 40% in a cohort of men with early stage prostate cancer, according to findings presented in advance of the of the 2011 Genitourinary Cancers Symposium.

Neil Fleshner, MD, MPH, head of Urology at the University Health Network in Toronto, Canada, presented data on behalf of the Reduction with Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) study.

“We used this phase 3 multicenter study to see if we could employ a commonly used drug to improve the compliance with active surveillance for men who elect this as their strategy to manage early stage prostate cancer,” Fleshner said. He noted that most of the men in this particular population were not likely to die from their disease.

“Many men who choose active surveillance have anxiety about disease progression,” he said. “We wanted to see if this drug could improve that.”

There were 302 eligible men aged 48 to 82 involved in the trial. Repeat 12-core biopsies were performed at 1.5 years and 3 years if there was no cause and at other times if biopsy was warranted or desired. “Some men simply no longer want to observe their cancer,” Fleshner said.

The primary endpoint was time to progression. Pathological progression was defined as a Gleason score greater than 6, at least 4 cores positive, or greater than 50% of any core positive. Therapeutic progression was defined as radical prostatectomy, radiation therapy or hormonal ablation, according to study results.

“Dutasteride (Avodart, GlaxoSmithKline) reduced the time to prostate cancer progression by about 40%,” Fleshner said. He noted the relative risk reduction of 38.9% (95% CI, 12.4%–57.4%). “This 40% reduction significantly improves adherence to active surveillance.”

Fleshner said that 23% of men in the placebo group and 36% of men in the treatment group had no cancer detected in their final biopsy.

“There is no evidence of increased Gleason score progression in the dutasteride arm compared to placebo,” he added. “Drug-related adverse events were similar to those previously reported for dutasteride.”

For more information:

Twitter Follow HemOncToday.com on Twitter.

    See more from Gastrointestinal Cancers Symposium